Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604

KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease

de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373

Business Information

Rodbard, H. W., Blonde, L., Ss, B., Brett, E. M., Cobin, R. H., Handelsman, Y., Hellman, R., Jellinger, P. S., Jovanovic, L. G., Levy, P., et al. (2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 695

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J. T., Christ‐Schmidt, H., Berman, L., & Pitt, B. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1410853 · Cited by 683

The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease

Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.132 · Cited by 655

Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639

Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial

Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015) · JAMA · doi:10.1001/jama.2015.7446 · Cited by 441

Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes

Collins, A. J., Pitt, B., Reaven, N. L., Funk, S. E., McGaughey, K. J., Wilson, D. J., & Bushinsky, D. A. (2017) · American Journal of Nephrology · doi:10.1159/000479802 · Cited by 411

Diabetes mellitus and electrolyte disorders

Liamis, G. L. (2014) · World Journal of Clinical Cases · doi:10.12998/wjcc.v2.i10.488 · Cited by 406

Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis

Kovesdy, C. P., Matsushita, K., Sang, Y., Brunskill, N. J., Carrero, J. J., Chodick, G., Hasegawa, T., Heerspink, H. J. L., Hirayama, A., Landman, G. W. D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy100 · Cited by 358

Physiology and pathophysiology of potassium homeostasis

Palmer, B. F., & Clegg, D. J. (2016) · AJP Advances in Physiology Education · doi:10.1152/advan.00121.2016 · Cited by 286

Cirrhosis and its complications: Evidence based treatment

Nusrat, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5442 · Cited by 297

Potentially Harmful Drug–Drug Interactions in the Elderly: A Review

Hines, L. E., & Murphy, J. E. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.10.004 · Cited by 275

2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension

Lee, H., Shin, J., Kim, G., Park, S., Ihm, S., Kim, H. C., Kim, K., Kim, J. H., Lee, J. H., Park, J., et al. (2019) · Clinical Hypertension · doi:10.1186/s40885-019-0124-x · Cited by 274

Management of severe hyperkalemia

Weisberg, L. S. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818f222b · Cited by 268

Use of Aldosterone Antagonists in Heart Failure

Albert, N. M. (2009) · JAMA · doi:10.1001/jama.2009.1493 · Cited by 262

Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy

Rossignol, P., Dobre, D., McMurray, J. J. V., Swedberg, K. B., Krum, H., van Veldhuisen, D. J., Shi, H. H., Messig, M., Vincent, J., Girerd, N., et al. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.113.000792 · Cited by 261

Electrolyte and Acid–Base Disturbances in Patients with Diabetes Mellitus

Palmer, B. F., & Clegg, D. J. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1503102 · Cited by 258

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G. S., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac401 · Cited by 238

Drug dosing adjustments in patients with chronic kidney disease.

Munar, M. Y., & Singh, H. (2007) · PubMed · Cited by 231

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril

Desai, A. S., Vardeny, O., Claggett, B. L., McMurray, J. J. V., Packer, M., Swedberg, K. B., Rouleau, J. L., Zile, M. R., Lefkowitz, M. P., Shi, V. C., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4733 · Cited by 226

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes

Bi, Y., Li, M., Liu, Y., Li, T., Lu, J., Duan, P., Xu, F., Dong, Q., Wang, A., Wang, T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2412006 · Cited by 224

Renin Angiotensin System Blockade in Kidney Transplantation: A Systematic Review of the Evidence

Hiremath, S. S., Fergusson, D. A., Doucette, S. P., Mulay, A. V., & Knoll, G. A. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01928.x · Cited by 210

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

Rosano, G. M. C., Tamargo, J. L., Kjeldsen, K. P., Lainščak, M., Agewall, S., Anker, S. D., Ceconi, C., Coats, A. J. S., Drexel, H., Filippatos, G. S., et al. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy015 · Cited by 204

Effects of dapagliflozin in stage 4 chronic kidney disease

Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021020167 · Cited by 201

Management of hyperkalaemia in chronic kidney disease

Kovesdy, C. P. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.168 · Cited by 201

Associations of serum potassium levels with mortality in chronic heart failure patients

Aldahl, M., Jensen, A.-S. C., Davidsen, L., Eriksen, M. A., Hansen, S. M., Nielsen, B. J., Krogager, M. L., Køber, L., Torp-Pedersen, C. T., & Søgaard, P. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx460 · Cited by 200

Abnormalities of Potassium in Heart Failure

Ferreira, J. P., Butler, J., Rossignol, P., Pitt, B., Anker, S. D., Kosiborod, M., Lund, L. H., Bakris, G. L., Weir, M. R., & Zannad, F. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.021 · Cited by 208

Clinical Management of Hyperkalemia

Palmer, B. F., Carrero, J. J., Clegg, D. J., Colbert, G. B., Emmett, M., Fishbane, S. N., Hain, D. J., Lerma, E. V., Onuigbo, M. A. C., Rastogi, A., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.014 · Cited by 204

Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Raebel, M. A. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 190

Prevalence and Factors Associated with Hyperkalemia in Predialysis Patients Followed in a Low-Clearance Clinic

Sarafidis, P. A., Blacklock, R. M., Wood, E., Rumjon, A., Simmonds, S., Fletcher-Rogers, J., Ariyanayagam, R., Al-Yassin, A., Sharpe, C. C., & Vinen, K. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01150112 · Cited by 187

Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension

Saha, C., Eckert, G., Ambrosius, W., Chun, T., Wagner, M. A., Zhao, Q.-Q., & Pratt, J. (2005) · HYPERTENSION · doi:10.1161/01.hyp.0000179582.42830.1d · Cited by 180

Renal Failure Associated with Cancer and Its Treatment

Humphreys, B. D., Soiffer, R. J., & Magee, C. (2004) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100843 · Cited by 177

Incidence and Predictors of Hyperkalemia in Patients With Heart Failure

Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.067 · Cited by 170

Validity of the International Classification of Diseases, Tenth Revision code for acute kidney injury in elderly patients at presentation to the emergency department and at hospital admission

Hwang, Y. J., Shariff, S. Z., Gandhi, S., Wald, R., Clark, E. G., Fleet, J. L., & Garg, A. X. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001821 · Cited by 167

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials

Ezekowitz, J. A., & McAlister, F. A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn543 · Cited by 167

Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

Lazich, I., & Bakris, G. L. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.008 · Cited by 164

Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease

Nakhoul, G., Huang, H., Arrigain, S., Jolly, S. E., Schold, J. D., Nally, J. V., & Navaneethan, S. D. (2015) · American Journal of Nephrology · doi:10.1159/000437151 · Cited by 168

Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review

Segall, L., Nistor, I., & Covic, A. C. (2014) · BioMed Research International · doi:10.1155/2014/937398 · Cited by 164

Effect of Patiromer on Reducing Serum Potassium and Preventing Recurrent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease on Raas Inhibitors

Pitt, B., Bakris, G. L., Bushinsky, D. A., Garza, D., Mayo, M. R., Stasiv, Y., Christ‐Schmidt, H., Berman, L., & Weir, M. R. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.402 · Cited by 159

Drug-Induced Hyperkalemia

Salem, C. B., Badreddine, A., Fathallah, N., Slim, R., & Hmouda, H. (2014) · Drug Safety · doi:10.1007/s40264-014-0196-1 · Cited by 151

Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America

Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145

Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes

Khanagavi, J., Gupta, T., Aronow, W. S., Shah, T. M., Garg, J., Ahn, C. W., Sule, S. S., & Peterson, S. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.42577 · Cited by 144

Treatment of hyperkalemia: something old, something new

Sterns, R. H., Grieff, M., & Bernstein, P. L. (2016) · Kidney International · doi:10.1016/j.kint.2015.11.018 · Cited by 143

Management of Hyperkalemia: An Update for the Internist

Kovesdy, C. P. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.040 · Cited by 140

Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System

Antoniou, T. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.142 · Cited by 140

Safety and Tolerability of Angiotensin-Converting Enzyme Inhibitor Versus the Combination of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Patients With Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Lakhdar, R., Al-Mallah, M. H., & Lanfear, D. E. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.11.008 · Cited by 129

A recent review of citrus flavanone naringenin on metabolic diseases and its potential sources for high yield-production

Karim, N., Jia, Z., Zheng, X., Cui, S., & Chen, W. (2018) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2018.06.012 · Cited by 129

Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)

Fried, L. F., Duckworth, W. C., Zhang, J. H., O’Connor, T., Brophy, M. T., Emanuele, N., Huang, G. D., McCullough, P. A., Palevsky, P. M., Seliger, S. L., et al. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03350708 · Cited by 128

Diagnosis and treatment of hyperkalemia

Palmer, B. F., & Clegg, D. J. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.17056 · Cited by 127

Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future

Rossignol, P., Legrand, M. M., Kosiborod, M., Hollenberg, S. M., Peacock, W. F., Emmett, M., Epstein, M., Kovesdy, C. P., Yılmaz, M. B., Stough, W. G., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.09.039 · Cited by 126

Hyperkalemia in Heart Failure

Sarwar, C. M. S., Papadimitriou, L., Pitt, B., Piña, I. L., Zannad, F. M., Anker, S. D., Gheorghiade, M., & Butler, J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.06.060 · Cited by 117

Systematic Review and Meta‐Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia

Meaney, C. J., Beccari, M. V., Yang, Y., & Zhao, J. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1906 · Cited by 115

Renal Tubular Acidosis and Management Strategies: A Narrative Review

Palmer, B. F., Kelepouris, E., & Clegg, D. J. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01587-5 · Cited by 115

Updates in hyperkalemia: Outcomes and therapeutic strategies

Kovesdy, C. P. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9384-x · Cited by 111

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Bushinsky, D. A., Williams, G. H., Pitt, B., Weir, M. R., Freeman, M. W., Garza, D., Stasiv, Y., Li, E., Berman, L., & Bakris, G. L. (2015) · Kidney International · doi:10.1038/ki.2015.270 · Cited by 110

Chronic Kidney Disease in Diabetes

McFarlane, P. A., Cherney, D. Z. I., Gilbert, R. E., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.004 · Cited by 112

Chronic Kidney Disease in Diabetes

McFarlane, P. A., Gilbert, R. E., MacCallum, L., & Senior, P. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.037 · Cited by 102

Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study

Fralick, M., Macdonald, E. M., Gomes, T., Antoniou, T., Hollands, S., Mamdani, M. M., & Juurlink, D. N. (2014) · BMJ · doi:10.1136/bmj.g6196 · Cited by 104

Poly(methyl methacrylate)s with Pendant Calixpyrroles and Crown Ethers: Polymeric Extractants for Potassium Halides

Aydogan, A., Coady, D. J., Kim, S. K., Akar, A., Bielawski, C. W., Márquez, M., & Sessler, J. L. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200803970 · Cited by 102

Potassium Metabolism and Management in Patients with CKD

Yamada, S., & Inaba, M. (2021) · Nutrients · doi:10.3390/nu13061751 · Cited by 101

Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension

Kovesdy, C. P., Appel, L. J., Grams, M. E., Gutekunst, L., McCullough, P. A., Palmer, B. F., Pitt, B., Sica, D. A., & Townsend, R. R. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.09.011 · Cited by 103

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Miao, Y., Dobre, D., Heerspink, H. J. L., Brenner, B. M., Cooper, M. E., Parving, H.-H., Shahinfar, S., Grobbee, D. E., & de Zeeuw, D. (2010) · Diabetologia · doi:10.1007/s00125-010-1922-6 · Cited by 100

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes—a Danish population-based cohort study

Thomsen, R. W., Nicolaisen, S. K., Hasvold, P., Sanchez, R. G., Pedersen, L. H., Adelborg, K., Egstrup, K., Egfjord, M., & Sørensen, H. T. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx312 · Cited by 96

Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension

Kovesdy, C. P., Appel, L. J., Grams, M. E., Gutekunst, L., McCullough, P. A., Palmer, B. F., Pitt, B., Sica, D. A., & Townsend, R. R. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.09.003 · Cited by 95

Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan

Kashihara, N., Kohsaka, S., Kanda, E., Okami, S., & Yajima, T. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.05.018 · Cited by 94

A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Carotid Intima-Media Thickness in Nondiabetic Hemodialysis Patients

Antonio Vukusich, C., Sonia Kunstmann, F., Varela, C., Daniela Gainza, K., Bravo, S., Sepúlveda, D., Cavada, G., Michea, L., & Marusic, E. T. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09421209 · Cited by 94

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled

Ferreira, J. P., Zannad, F. M., Butler, J., Filipattos, G., Ritter, I., Schueler, E., Kraus, B. J., Pocock, S., Anker, S. D., & Packer, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac306 · Cited by 92

Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management

de Sousa, A. G. P., Cabral, J. V., El-Feghaly, W. B., sousa, L. K. L., & Nunes, A. B. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i5.101 · Cited by 93

Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers

Raebel, M. A., McClure, D. L., Simon, S. R., Chan, K. A., Feldstein, A. C., Andrade, S. E., Lafata, J. E., Roblin, D. W., Davis, R. L., Gunter, M. J., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1217 · Cited by 88

True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis

Vukadinović, D., Lavall, D., Vukadinović, A. N., Pitt, B., Wagenpfeil, S., & Böhm, M. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.03.011 · Cited by 90

Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021

Banerjee, D., Winocour, P. H., Chowdhury, T. A., De, P., Wahba, M. M., Montero, R., Fogarty, D. G., Frankel, A., Karalliedde, J. J., Mark, P. B., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02587-5 · Cited by 92

A Physiologic-Based Approach to the Evaluation of a Patient With Hypokalemia

Palmer, B. F. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.07.010 · Cited by 86

Pathophysiology, therapy, and oral implications of renal failure in children and adolescents: an update.

Davidovich, E., Davidovits, M., Eidelman, E., Schwarz, Z., & Bimstein, E. (2005) · PubMed · Cited by 85

A retrospective study of emergency department potassium disturbances: severity, treatment, and outcomes

Singer, A. J., Thode, H. C., & Peacock, W. F. (2017) · Clinical and Experimental Emergency Medicine · doi:10.15441/ceem.16.194 · Cited by 83

Metabolic Complications Associated With Use of Diuretics

Palmer, B. F. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.09.009 · Cited by 83

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

Bamberg, K., Johansson, U., Edman, K., William‐Olsson, L., Myhre, S., Gunnarsson, A., Geschwindner, S., Aagaard, A., Granqvist, A., Jaisser, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193380 · Cited by 82

Proteinuria as a Therapeutic Target in Patients with Chronic Kidney Disease

Palmer, B. F. (2007) · American Journal of Nephrology · doi:10.1159/000101958 · Cited by 82

Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes

Thomsen, R. W., Nicolaisen, S. K., Hasvold, P., García‐Sánchez, R., Pedersen, L. H., Adelborg, K., Egfjord, M., Egstrup, K., & Sørensen, H. T. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008912 · Cited by 81

New Potassium Binders for the Treatment of Hyperkalemia

Pitt, B., & Bakris, G. L. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.04889 · Cited by 79

How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies

Humphrey, T. J. L., Davids, M. R., Chothia, M., Pecoits‐Filho, R., Pollock, C. A., & James, G. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab243 · Cited by 80

Potassium and Its Discontents

Ellison, D. H., Terker, A. S., & Gamba, G. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015070751 · Cited by 76

Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring

Raebel, M. A., Ross, C. A., Xu, S., Roblin, D. W., Cheetham, C., Blanchette, C. M., Saylor, G., & Smith, D. H. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1228-x · Cited by 75

Targeting Outpatient Drug Safety

Herwaarden, M. F. W., Kramers, C., Sturkenboom, M., van den Bemt, P. M. L. A., & Smet, P. A. G. M. D. (2012) · Drug Safety · doi:10.2165/11596000-000000000-00000 · Cited by 75

Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena

Epstein, M. (2016) · Kidney International Supplements · doi:10.1016/j.kisu.2016.01.004 · Cited by 76

Validity of the International Classification of Diseases 10th revision code for hyperkalaemia in elderly patients at presentation to an emergency department and at hospital admission

Fleet, J. L., Shariff, S. Z., Gandhi, S., Weir, M. A., Jain, A. K., & Garg, A. X. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-002011 · Cited by 71

Analysis of Factors Causing Hyperkalemia

Takaichi, K., Takemoto, F., Ubara, Y., & Mori, Y. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6415 · Cited by 69

Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management

Hundemer, G. L., & Sood, M. M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105835 · Cited by 67

Effects of Presentation and Electrocardiogram on Time to Treatment of Hyperkalemia

Freeman, K., Feldman, J. A., Mitchell, P. M., Donovan, J., Dyer, K. S., Eliseo, L. J., White, L. F., & Temin, E. S. (2008) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2008.00058.x · Cited by 67

Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia

Barrera‐Chimal, J., Prince, S., Fadel, F., Moghrabi, S. E., Warnock, D. G., Kolkhof, P., & Jaisser, F. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014121216 · Cited by 65

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review

Beccari, M. V., & Meaney, C. J. (2017) · Core evidence · doi:10.2147/ce.s129555 · Cited by 65

Serum Potassium in the PARADIGM-HF Trial

Ferreira, J. P., Mogensen, U. M., Jhund, P. S., Desai, A. S., Rouleau, J. L., Zile, M. R., Rossignol, P., Zannad, F. M., Packer, M., Solomon, S. D., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1987 · Cited by 64

Clinical-pharmacist intervention reduces clinically relevant drug–drug interactions in patients with heart failure: A randomized, double-blind, controlled trial

Roblek, T., Detiček, A., Leskovar, B., Šuškovič, S., Horvat, M., Belic, A., Mrhar, A., & Lainščak, M. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.10.206 · Cited by 63

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis

Yavin, Y., Mansfield, T. A., Ptaszynska, A., Johnsson, K. M., Parikh, S. J., & JOHNSSON, E. K. (2016) · Diabetes Therapy · doi:10.1007/s13300-015-0150-y · Cited by 62

Blood pressure drug therapy and electrolyte disturbances

Liamis, G. L., Milionis, H. J., & Elisaf, M. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01860.x · Cited by 61

CKD as an Underrecognized Threat to Patient Safety

Fink, J. C., Brown, J., Hsu, V. D., Seliger, S. L., Walker, L. D., & Zhan, M. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.016 · Cited by 60

Hyperkalemia in patients with heart failure: Incidence, prevalence, and management

Desai, A. S. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0037-1 · Cited by 59

Risk of hyperkalemia and combined use of spironolactone and long‐term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real‐life data: a population‐ and insurance‐based cohort

Abbas, S., Ihle, P., Harder, S., & Schübert, I. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3748 · Cited by 59

Evaluation of an Individualized Dose Titration Regimen of Patiromer to Prevent Hyperkalaemia in Patients with Heart Failure and Chronic Kidney Disease

Pitt, B., Bushinsky, D. A., Kitzman, D. W., Ruschitzka, F. T., Metra, M., Filippatos, G. S., Rossignol, P., Mond, C. D., Garza, D., Berman, L., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12265 · Cited by 58

Systematic Review Of Hyperkalemia Due To Angiotensin Enzyme Converting Inhibitors

Aggarwal, S., Topaloglu, H., & Kumar, S. (2015) · Value in Health · doi:10.1016/j.jval.2015.09.898

Systematic Review of Burden of Hyperkalemia due to Angiotensin Enzyme Converting Inhibitors

Aggarwal, S., Kumar, S., & Topaloglu, H. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.082

Hyperkalemia and Inhibitors of the Renin–Angiotensin–Aldosterone System

Segal, A. Z. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412023512321 · Cited by 2

Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Closer Look at Hyperkalemia

Chung, S., & Park, C. W. (2011) · The Korean Journal of Internal Medicine

Hyperkalemia Associated with Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Raebel, M. A. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00258.x · Cited by 190